We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
+$387M
Cap. Flow
+$515M
Cap. Flow %
30.44%
Top 10 Hldgs %
76.07%
Holding
31
New
6
Increased
13
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$129M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$45.8M
3
CLDX icon
Celldex Therapeutics
CLDX
+$43.6M
4
IMCR icon
Immunocore
IMCR
+$38.7M
5
CGON icon
CG Oncology
CGON
+$25.6M

Top Sells

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$21.4M
2
VERA icon
Vera Therapeutics
VERA
+$5.25M
3
NTRA icon
Natera
NTRA
+$2.97M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$2.86M
5
COGT icon
Cogent Biosciences
COGT
+$1.34M

Sector Composition

Rank Sector Weight
1 Healthcare 89.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$320M 18.92%
2,022,098
-20,373
-1% -$2.97M
PCVX icon
2
Vaxcyte
PCVX
$7.89B
$191M 11.31%
2,336,796
+1,297,508
+125% +$129M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$176M 10.39%
+300,000
New +$177M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.77B
$128M 7.56%
5,064,207
+1,605,598
+46% +$43.6M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.84B
$113M 6.66%
8,520,000
+2,677,075
+46% +$45.8M
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$83.8M 4.95%
6,560,835
-1,771,852
-21% -$21.4M
CGON icon
7
CG Oncology
CGON
$6.11B
$72.3M 4.27%
2,519,705
+748,900
+42% +$25.6M
COGT icon
8
Cogent Biosciences
COGT
$6.79B
$71M 4.2%
9,105,000
-134,731
-1% -$1.34M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.37B
$68.3M 4.04%
9,085,368
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$63.8M 3.77%
3,326,262
+814,967
+32% +$17.7M
VERA icon
11
Vera Therapeutics
VERA
$2.54B
$61.7M 3.64%
1,457,910
-118,639
-8% -$5.25M
WVE icon
12
Wave Life Sciences
WVE
$1.12B
$60.6M 3.58%
4,899,497
– –
BEAM icon
13
Beam Therapeutics
BEAM
$2.58B
$43.6M 2.57%
1,756,158
+454,073
+35% +$11.6M
IMCR icon
14
Immunocore
IMCR
$1.78B
$36.2M 2.14%
+1,225,576
New +$38.7M
ENGN icon
15
enGene Therapeutics
ENGN
$122M
$33.2M 1.96%
4,994,090
+3,257,863
+188% +$25.3M
TVTX icon
16
Travere Therapeutics
TVTX
$5.33B
$31.4M 1.86%
1,802,750
+431,239
+31% +$7.63M
LQDA icon
17
Liquidia Corp
LQDA
$7.67B
$26.7M 1.58%
2,266,328
– –
IRWD icon
18
Ironwood Pharmaceuticals
IRWD
$611M
$20.8M 1.23%
4,685,563
+1,000,000
+27% +$4.06M
TSVT
19
DELISTED
2seventy bio
TSVT
$17.5M 1.03%
5,953,825
– –
CGEM icon
20
Cullinan Oncology
CGEM
$1.05B
$15.3M 0.9%
+1,252,738
New +$18M
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.75B
$15.1M 0.89%
390,792
-65,577
-14% -$2.86M
TYRA icon
22
Tyra Biosciences
TYRA
$1.82B
$7.37M 0.44%
530,478
+62,531
+13% +$1.13M
BNR
23
Burning Rock Biotech
BNR
$94.4M
$6.72M 0.4%
994,883
+5,666
+0.6% +$26.1K
STRO icon
24
Sutro Biopharma
STRO
$379M
$6.7M 0.4%
364,145
+157,500
+76% +$4.81M
AMRN
25
Amarin Corp
AMRN
$284M
$6.02M 0.36%
620,731
– –
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Kynam Capital Management held 31 positions worth $1.69B, up 30% from $1.3B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Kynam Capital Management deployed $515M of net new capital in Q4 2024, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Immunocore: 1,225,576 shares worth $36.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $21.4M trimmed.

  • Kynam Capital Management's largest Q4 2024 buy was Immunocore: 1,225,576 shares worth $36.2M.
  • Kynam Capital Management added most to Vaxcyte in Q4 2024, an estimated $129M increase.
  • Kynam Capital Management's biggest Q4 2024 reduction was Dynavax Technologies, cutting an estimated $21.4M.
  • Kynam Capital Management's ten largest holdings make up 76% of its $1.69B portfolio in Q4 2024.
  • Kynam Capital Management opened 6 new positions and closed 1 in Q4 2024.
  • Kynam Capital Management's portfolio value rose 30% quarter-over-quarter to $1.69B.

Based on Kynam Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.